Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate...
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
supporting the niraparib-based combination regimen as a new standard of care for patients with BRCA mutations Results demonstrate a delay in disease progression and an early trend toward improved overall survival with the niraparib and abiraterone acetate regimen versus standard of care in the treatment of mHSPC BEERSE, Belgium, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an indication extension for AKEEGA ® (niraparib and abiraterone acetate dual action tablet). The recommendation is for niraparib and abiraterone acetate with prednisone or prednisolone (AAP) in combination with androgen deprivation therapy (ADT) and BRCA1/2 mutations (germline and/or somatic). "Patients with metastatic hormone-sensitive prostate cancer who carry BRCA1/2 mutations face a more aggressive disease with survival outcomes that are significantly shorter, compare
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF SymposiumBusiness Wire
- BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? [Yahoo! Finance]Yahoo! Finance
- Alcon's Precision7 Weekly Lenses Test Comfort Claims And Growth Hopes [Yahoo! Finance]Yahoo! Finance
- 5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/6/26 - Form 4
- 2/5/26 - Form 144
- 2/5/26 - Form SCHEDULE
- JNJ's page on the SEC website